RESPONSE: Re: Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles by Lowy, Douglas R. et al.
Re: Specific Antibody Levels at
the Cervix During the
Menstrual Cycle of Women
Vaccinated With Human
Papillomavirus 16 Virus-Like
Particles
We read with interest the article by
Nardelli-Haefliger et al. (1) in which the
authors reported an approximate nine-
fold reduction in cervical anti-human
papillomavirus 16 (HPV16) immuno-
globulin (Ig; specific IgG and total IgG
and IgA) levels at the time of ovulation
in 11 women who received aluminum-
free (i.e., adjuvant-free) HPV16 L1
virus-like particle (VLP) vaccine syn-
thesized in a baculovirus system (1).
The authors hypothesized that the effi-
cacy of prophylactic HPV16 L1 VLP
vaccines may be reduced during the
peri-ovulatory phase in women who are
not using hormonal contraception.
We recently reported (2) the primary
efficacy results of a multicenter,
placebo-controlled trial of a prophylac-
tic HPV16 L1 VLP vaccine in 2392
women aged between 16 and 23 years.
The HPV16 L1 VLPs were synthesized
in yeast and formulated on aluminum
adjuvant. In the primary efficacy cohort,
the vaccine was found to be 100% ef-
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fective in preventing persistent cervico-
vaginal HPV16 infection and related
cervical intraepithelial neoplasia for a
median of 17.4 months following the
completion of vaccination.
In our study (2), information on con-
traceptive use was collected at each visit
and contraceptive methods were divided
into ovulation-suppressing contracep-
tives (i.e., oral or parenteral hormone
contraceptives) or non-suppressing con-
traceptives (i.e., barrier, abstinence,
rhythm). The extent of use of these cat-
egories of contraceptives was assessed
in two ways: 1) the number of individ-
uals who reported use of an ovulation-
suppressing contraceptive on at least one
study visit and 2) the overall duration of
exposure to ovulation-suppressing con-
traceptives, measured in woman-years at
risk. In the primary efficacy cohort, 77%
of women reported use of an ovulation-
suppressing contraceptive on at least
one study visit. However, many women
used these products for only short periods
of time or intermittently. Thus, ovulation-
suppressing contraceptives were used in
only 54% of the woman-years at risk in
this cohort. Hence, because vaccine ef-
ficacy was observed to be 100%, ovula-
tion and potential fluctuations in cervical
anti-HPV16 IgG levels did not appear to
affect vaccine efficacy in our study.
In light of our study (2), the findings
of Nardelli-Haefliger et al. (1) can lead
to one of three alternate hypotheses.
First, although vaccine-induced anti-
HPV16 levels in cervicovaginal secre-
tions may fluctuate during the ovulatory
cycle, they remain sufficiently high to
prevent HPV16 infection. Second, the
efficacy of HPV16 L1 VLP vaccines is
not affected by anti-HPV16 levels in
cervical secretions—that is, because the
HPV16 infectious cycle depends criti-
cally on infection of the basal cell layer
of the cervical epithelium, the delivery
of anti-HPV16 IgG by extravasated
blood may be a more important deter-
minant of vaccine efficacy. Third, the
impact of ovulation-induced fluctuations
in cervical anti-HPV16 IgG levels on
HPV vaccine efficacy may be subtle;
therefore, a larger study with longer
follow-up would be required to detect
such an effect.
Assuming that vaccine-induced anti-
HPV16 in cervicovaginal secretions is
an important mechanism for the vac-
cine’s protective effect, cervical IgG
levels in the peri-ovulatory period
would have to drop below the level re-
quired for maintenance of the vaccine’s
protective efficacy to result in a clinical
impact. Although such a level has not
been defined, it stands to reason that
vaccines that induce high levels of anti-
HPV16 IgG are less likely than less im-
munogenic vaccines to be affected by
peri-ovulatory fluctuations in cervical
anti-HPV16 Ig levels. The vaccine for-
mulation used in the study by Nardelli-
Haefliger et al. (1) contained no adju-
vant. In our experience, the use of
aluminum adjuvant in the formulation of
HPV16 L1 VLP vaccines increases se-
rum anti-HPV16 IgG levels more than
10-fold compared with an adjuvant-free
formulation. If our vaccine induced
higher anti-HPV16 levels than those in-
duced by the vaccine used by Nardelli-
Haefliger et al., then our vaccine may be
less prone to clinically meaningful de-
creases in cervical IgG levels than the
formulation used by Nardelli-Haefliger
et al. (1).
We have reported that vaccine-
induced anti-HPV16 responses decline
over time (2). Women in our study were
followed for a median of 17.4 months
after completing the vaccination. How-
ever, women remain at risk for HPV
infection for several years. To fully ad-
dress the impact in peri-ovulatory anti-
HPV16 IgG levels on vaccine efficacy,
it will be important to assess the dura-
tion of HPV16 L1 VLP vaccine efficacy
over a longer period of follow-up.
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RESPONSE
We thank Drs. Barr and Koutsky for
their comments related to our recently
published article, in which we reported
that human papillomavirus 16 (HPV16)
antibody levels at the cervix, following
systemic immunization with an HPV16
virus-like particle (VLP) vaccine, vary
substantially during the course of the
menstrual cycle (1). We agree that long-
term studies of vaccinees are needed to
determine whether, and to what degree,
these variations in HPV16 antibody lev-
els may influence vaccine efficacy sev-
eral years after vaccination. As noted by
Drs. Barr and Koutsky and by ourselves
(2), such efficacy results should help to
clarify whether serum antibody or cer-
vical antibody levels are the primary
correlate of vaccine efficacy. In ongoing
long-term efficacy studies, it may be
useful to distinguish between the group
of women who, after the vaccination
period, do not use hormonal contracep-
tives at all and the group of women who
use hormonal contraceptives intermit-
tently, because it may be difficult to
infer, with the latter group of women,
whether their risk of HPV exposure will
be similar during intervals on and off
hormonal contraceptives.
In addition, we would also like to
point out that the magnitude of the fluc-
tuation we observed in HPV16 antibody
levels at the cervix during the menstrual
cycle was also seen for total immuno-
globulin G levels at the cervix (1).
Therefore, we believe that the observed
menstrual cycle–dependent changes in
HPV16 antibody levels at the cervix
have nothing to do with our HPV16
VLP vaccine having been formulated
without adjuvant, and we would expect
that analogous fluctuations in antibody
levels would be seen following systemic
immunization with any VLP-based vac-
cine. We also note that, in apparent con-
trast to the observations of Drs. Barr and
Koutsky, we did not find increased im-
munogenicity from the addition of alu-
minum adjuvant to the 50-g dose of
VLPs used in our study (1), although we
have observed an adjuvant effect from
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aluminum when given with a 10-g
dose of VLPs (3).
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